Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
P100, you say 3-5m under forecast.
From half year results, they forecast around 4m in S2.
"Predicted Q3 2022 revenue of circa £2.0m, with similar levels expected in Q4 2022, "
So you think our revenues could be of minus 1m ?
Me neither Kaeren.
Katalyst with Versalab : https://twitter.com/Larry64450205/status/1616443670521319425?t=aMUkzU2YZgBcwPwXe3QPew&s=19
https://twitter.com/NovacytGroup/status/1616345154989826051?t=pIafYGk_z4b5MJAYA5ceuA&s=19
The results came out After market, at 18:00 (french Time).
So for the SP, we will see tomorrow what it's doing !
Also, i would add the evolution in their global revenue in 2022. S1 brought 142.2m€ , S2 : 54.4m€.
What i would have liked to know is CAB... No info...
You have the most recent post on there too :
4.0
?????
Current Employee, more than 1 year
Good place of work.
Jan 13, 2023 — Anonymous Employee
Recommend
CEO Approval
Business Outlook
Pros
Flexible working. Good team manager.
Cons
Job instability in the last year
I did not told gov Was going to pay up tomorrow.
But of course i do wish that this matter Was closed, and with a good outcome for ncyt. Not even sure you Want that p100.
"There is strong evidence that the principal objective of CTDA (Objective 1) has been met, namely to improve the quality of tests available on the private market by setting minimum performance thresholds and reducing the incidence of false positive and negative results.
The number of applications and successful and unsuccessful outcomes demonstrate a consistent supply of tests coming through the approval process and would indicate that, despite some difficulties, companies with suitably robust procedures and evidence are able to successfully satisfy the requirements of CTDA and get their tests onto the UK market.
While the approved register does not allow consumers to compare tests (Objective 4) based on performance, it allows users to confidently select products that had met CTDA requirements and were able to meet defined minimum performance thresholds, improving consumer information and filtering out poor products (Objective 2)."
But this is good to read this, as Exsig, just like genesig 3G are meeting those requirements and have been validated on CTDA.
It does prove that those tests are working well.
So DHSCs claim looking like they have some lead in the wing. Just like privateeye story.
Interesting view 21ats.
P100, did i create this website ?
https://www.eurofins.com/contact-us/worldwide-interactive-map/united-kingdom/eurofins-microgen/
Eurofins Microgen
Unit 1, Watchmoor Point
Camberley
GU15 3AD
Surrey
United Kindom
info@microgenbioproducts.com
microgenbioproducts.com
Something is weird no ?
Same adress, same name, sending on ncyts website, etc...
More than that i dont know.
Neilrich, eurofins has tons of subsidiaries with différents names. So that doesnt choc me.
But makes no sense that ncyt didnt clearly told us they sold microgen. And for how much. And what assays and assets ofnlicrogen did they kept or sold etc
Gizmo, the mpx test is from primerdesign, so i dont get what you mean ?
It's nice but it has nothing to do with microgen. Other "COVID stocks" like biosynex are also up. More likely news about china etc
It will be hard to maintain this rise in the time without concrete things imho.
If anyone Can make sense of it
https://twitter.com/Larry64450205/status/1608133427638816771?t=hjPTFrgVzbjEcfXBNxLOyQ&s=19
And of course those ones Never got any problem to get paid :
Innova Medical landed Covid contracts valued at £4 billion via the ‘VIP’ lane after its UK partner, a company trading under the name ‘Tried & Tested’ contacted Boris Johnson’s former advisor, Dominic Cummings.
Surescreen Diagnostics landed a £500m contract after Liam Fox MP referred the firm to Matt Han**** – Surescreen subsequently donated £20,000 to Liam Fox.
Matt Han**** assisted Ecolog International onto the ‘VIP’ lane after being contacted by Genix Healthcare – a company that has donated £156,000 to the Conservative Party. Han****’s Department paid Ecolog £38m in 2021, after the Government decided not to proceed with previously contracted Covid work.
https://www.gov.uk/government/publications/covid-19-testing-procurement/covid-19-testing-procurement
Primer design as a "Existing DHSC supplier". No lord or whatever like some others...
The "funny" part :
"Evaluating offers
All offers were evaluated by commercial professionals against the same criteria, assessing value for money and their ability to meet the government’s rigorous standards and deliver the service required. The COVID-19 testing services provided by suppliers were often for complex or innovative scientific products or services so where necessary, an expert technical evaluation process was also carried out."
So Exsig was good enough to get a contract ,no ... ?
I put that here again, thks to B2. It's not that old :
Transcript of YouTube Novacyt AGM Recording, august 2022, Question and Answer session only:
"Q3 The next question is about our current cash position (around £100 million) and whether we would buy-back shares or how we would utilise that cash.
James McCarthy answered
I think share buy back isn't ruled out, we also haven't declared the dividend for this year and in our annual accounts I think we should look at that in the wider capital structure of the company. We feel that the balance sheet gives us an opportunity to invest in the right areas of the business, we are being cautious about that. I think we'd like to make the right choices. We still feel we can create shareholder value by investing those funds, I think clearly if we got to a point that we felt that we could no longer do that we would look at the most economic way to return that cash to shareholders so that would be a dividend, or a capital reduction or share buyback that is something we would look at in the overall capital structure."